ArticleFrontiers in medicine2026
Effects of
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aging is an irreversible process shaped by genetic and environmental factors. Beyond physical and mental decline, it involves complex biological mechanisms. Programmed theories propose aging follows a biological clock, while error theories attribute it to environmental damage. A key mechanism is telomere shortening; once critically shortened, cells enter senescence. Telomerase preserves telomeres, but its activity decreases with age. Aging also causes cognitive decline, measurable through tools like electroencephalography (EEG). Study design: This two-arm, double blind, placebo-controlled superiority randomized controlled trial evaluates the effects of Outcomes: Primary outcomes include telomerase activity and telomere length (qPCR). Secondary outcomes include neurocognitive function [validated MoCA for the Sri Lankan population], neurophysiological functions-nerve conduction test (NCT) for upper and lower limb nerves and brain electrical activity (EEG)-and assessing health-related quality of life (HRQoL) using a validated questionnaire. Discussion: This trial will provide evidence on BMFD's potential to preserve telomere length, support cognitive functions, and slow aging processes. Integrating Ayurvedic principles, including constitution ( Clinical trial registration: https://doi.org/10.1186/ISRCTN64126920, identifier ISRCTN64126920.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.